# Patient-Trial Match Report

*Generated: 2026-01-05 18:27:00*

## Patient Profile

- **Age**: 65
- **Sex**: Male
- **Cancer Type**: NSCLC
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 65-year-old male diagnosed with Stage IV non-small cell lung cancer (adenocarcinoma) in March 2024. KRAS G12C mutation confirmed by NGS (FoundationOne CDx). Initial treatment with carboplatin/pemetrexed + pembrolizumab x6 cycles achieved partial response. Progressive disease noted on surveillance CT in November 2025 with new hepatic metastases. Currently asymptomatic with mild dyspnea on exertion. No history of autoimmune disease. Former smoker (30 pack-years, quit 2019). Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 12
- **LLM scored**: 88

## ðŸŸ¢ HIGH Likelihood (34 trials)

### [NCT06881784](https://clinicaltrials.gov/study/NCT06881784)

**RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 95%

**âœ“ Supporting Factors:**
- Age: 65
- ECOG status: 1
- Pathologically confirmed NSCLC
- Measurable disease confirmed with hepatic metastases
- Prior therapies: carboplatin/pemetrexed and pembrolizumab (includes anti-PD-1 agent and platinum-based chemotherapy)
- Documented RAS mutation: KRAS G12C

**Assessment:**
> The patient's cancer type matches the trial's indication as it focuses on metastatic NSCLC with KRAS mutations. The patient has also received the required prior therapies and meets the ECOG performance status.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 95%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC, matching trial conditions studied
- Patient is 65 years old, above minimum age requirement
- ECOG status is 1, which meets trial criteria
- Patient has adequate organ function: Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k
- Prior therapies include treatment with immunotherapy and chemotherapy, which aligns with trial's requirement for previously treated patients
- Biomarker: KRAS G12C mutation confirmed, which is required for trial eligibility

**Assessment:**
> The patient meets all critical eligibility criteria, including matching cancer type and treatment history necessary for trial participation. There are no conflicts or uncertainties.

---

### [NCT03851445](https://clinicaltrials.gov/study/NCT03851445)

**LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Pathologically proven non-small cell lung cancer (NSCLC) confirmed by tumor biopsy
- Stage IV disease as defined by clinical details
- Prior systemic therapy with carboplatin/pemetrexed and pembrolizumab
- ECOG status of 1
- Age 65 (â‰¥ 18 years)
- No brain metastases
- No history of autoimmune disease
- Adequate organ function (creatinine 1.1, ANC 3.2, platelets 245k)

**? Uncertainties:**
- Adequate tumor tissue availability not explicitly confirmed
- Details on the specific requirement of ctDNA testing and fresh biopsy if needed are not provided
- Confirmatory biopsy details were not mentioned

**Assessment:**
> The patient's cancer type is NSCLC, which matches the trial. The patient has Stage IV disease and has received prior treatment, which aligns with the trial's focus on previously treated patients. The ECOG status and age also meet eligibility requirements. Minor uncertainties exist regarding the adequacy of tumor tissue and specific biopsy requirements, but overall the patient demonstrates a high likelihood of eligibility.

---

### [NCT05671510](https://clinicaltrials.gov/study/NCT05671510)

**Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors**

- **Sponsor**: OncoC4, Inc.
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a histologically confirmed diagnosis of metastatic NSCLC.
- Patient has prior treatment with at least 6 cycles of a PD-L1 inhibitor.
- Patient has ECOG status of 1.
- Patient does not have symptomatic brain metastases.
- Patient's organ function tests (creatinine, LFTs, ANC, platelets) are normal.

**Assessment:**
> The patient's diagnosis of metastatic non-small cell lung cancer (NSCLC) aligns with the trial's focus. The patient has previously received PD-L1 inhibitor therapy and has a suitable ECOG status. There are no conflicts found in eligibility criteria.

---

### [NCT05853575](https://clinicaltrials.gov/study/NCT05853575)

**A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65 (greater than 18 years old)
- Cancer type: Stage IV non-small cell lung cancer (adenocarcinoma)
- Biomarker: KRAS G12C mutation confirmed by NGS
- Prior treatment: carboplatin/pemetrexed and pembrolizumab (immune checkpoint inhibitor)
- ECOG status: 1
- No brain metastases

**? Uncertainties:**
- Normal organ function tests were reported, but specific thresholds are not provided for creatinine and liver function tests, which could affect eligibility.

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial criteria, they are previously treated, and they have no contraindications related to brain metastases or significant organ dysfunction. However, while organ function tests are reported as normal, confidence remains slightly reduced due to unspecified exact values.

---

### [NCT06162221](https://clinicaltrials.gov/study/NCT06162221)

**A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 65, which is above 18 years
- ECOG status is 1
- Pathologically documented KRAS G12C-mutated NSCLC
- Prior therapy with carboplatin/pemetrexed and pembrolizumab aligns with inclusion criteria

**? Uncertainties:**
- None - all relevant criteria met

**Assessment:**
> The patient's NSCLC with a KRAS G12C mutation aligns with the trial's focus on RAS mutations. The patient has prior treatments but meets the criteria for the arms that include previously treated patients. All other criteria, including age and ECOG status, are within acceptable ranges.

---

### [NCT06660407](https://clinicaltrials.gov/study/NCT06660407)

**Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- ECOG status: 1
- Stage IV non-small cell lung cancer progressing on standard of care first line immunotherapy
- Absolute neutrophil count (ANC): 3.2
- Platelet count: 245k
- Creatinine: 1.1

**Assessment:**
> The patient has a confirmed diagnosis of Stage IV non-small cell lung cancer and is progressing on first-line immunotherapy, which matches the trial's inclusion criteria. The ECOG status is acceptable, and relevant lab values support eligibility. There are no conflicts or uncertainties that would lead to exclusion.

---

### [NCT06907615](https://clinicaltrials.gov/study/NCT06907615)

**An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Shanghai Henlius Biotech
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient diagnosed with Stage IV non-small cell lung cancer (NSCLC)
- Patient has a confirmed KRAS G12C mutation
- ECOG status of 1
- Prior treatment with platinum-based chemotherapy (carboplatin/pemetrexed) and immunotherapy (pembrolizumab)
- No brain metastases

**? Uncertainties:**
- Adequate organ function test results are not explicitly confirmed
- Measurable lesions status not provided

**Assessment:**
> The patient has Stage IV NSCLC, which matches the trial indication. The patient has already received systemic treatments as required for participation in the study. Supporting factors like ECOG status and lack of brain metastases further strengthen the eligibility assessment, though some uncertainties remain regarding organ function and measurable lesions.

---

### [NCT07227025](https://clinicaltrials.gov/study/NCT07227025)

**A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC characterized by a KRAS G12C mutation.
- ECOG status is 1.

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic NSCLC with a KRAS G12C mutation. The patient has previously treated cancer with appropriate therapies and meets the ECOG performance status requirement.

---

### [NCT07288034](https://clinicaltrials.gov/study/NCT07288034)

**Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 2
- **Status**: Not yet recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: NSCLC matches trial
- ECOG status: 1 matches trial criteria
- Age: 65 meets age requirement (> 18 years)
- PD-L1: TPS 40% meets criteria for PD-L1 expression
- Prior therapies: received anti-PD1/PDL1 and only up to 6 cycles of pembrolizumab, aligning with previously treated criteria
- Brain metastases: none
- Creatinine: 1.1 meets organ function criteria
- Absolute neutrophil count (ANC): 3.2 meets eligibility criteria
- Platelets: 245k meets eligibility criteria

**âœ— Potential Conflicts:**
- No active disease criteria conflicts noted

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial criteria and the treatment line is appropriate as he is previously treated but eligible. All supporting factors confirm his eligibility, leading to a high confidence in fit for the trial.

---

### [NCT05815173](https://clinicaltrials.gov/study/NCT05815173)

**Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: NYU Langone Health
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 65, which is above 18 years
- ECOG status is 1
- Histologically confirmed diagnosis of NSCLC (adenocarcinoma)
- Patient has KRAS G12C mutation confirmed by NGS
- Demonstrated progression of disease following treatment with anti-PD-(L)-1 and platinum-based chemotherapy
- Patient has no brain metastases
- Absolute neutrophil count is 3.2 (greater than 1.5)
- Platelet count is 245k (greater than 100)
- Normal liver function tests
- Patient can swallow and retain orally administered medication

**? Uncertainties:**
- Confirmed renal clearance (eGFR) is not provided in the profile

**Assessment:**
> The patient's cancer type matches the trial's indication for advanced NSCLC with KRAS G12C mutation. The patient has previously been treated and demonstrates disease progression post-treatment, which aligns with the study criteria. All major eligibility criteria are met, with the only uncertainty being renal function that is not explicitly confirmed.

---

### [NCT06130254](https://clinicaltrials.gov/study/NCT06130254)

**Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma) with a confirmed KRAS G12C mutation.
- Patient has progressive disease after one line of systemic therapy.
- ECOG status is 1.
- No brain metastases.
- Absolute neutrophil count (ANC) is 3.2 (greater than 1.5 x 10^9/L).
- Platelet count is 245k (greater than 100,000/mm3).
- Life expectancy is at least 3 months.

**? Uncertainties:**
- Not all organ function lab results provided (e.g., hemoglobin level, total bilirubin, AST/ALT).

**Assessment:**
> The patient's cancer type, NSCLC with KRAS G12C mutation, aligns with the trial's focus, and they have previously received treatment, meeting the trial requirements for previous systemic therapy. Their ECOG status and absence of brain metastases further support eligibility. However, certain laboratory values are not confirmed.

---

### [NCT06343402](https://clinicaltrials.gov/study/NCT06343402)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically documented metastatic non-small cell lung cancer with a KRAS G12C mutation
- ECOG status is 1

**Assessment:**
> The patient's NSCLC with KRAS G12C mutation matches the trial's indication. He is also previously treated, which aligns with the trial allowing previously treated patients. The ECOG status meets the requirements. There are no reported conflicts or uncertainties.

---

### [NCT06249282](https://clinicaltrials.gov/study/NCT06249282)

**A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC which is the cancer type being studied.
- Patient has a confirmed KRAS G12C mutation, which is required for trial eligibility.
- ECOG status of 1 is within acceptable range (â‰¤ 2).
- Prior therapies include treatments consistent with the eligibility criteria.
- Patient has measurable disease based on the clinical details provided.
- ANC of 3.2 is above the required minimum of 1,500/mmÂ³.
- Platelets of 245k are above the required minimum of 100,000/mmÂ³.

**? Uncertainties:**
- Patient's total bilirubin, AST, ALT, and creatinine clearance levels not provided for confirmation.

**Assessment:**
> The patient's NSCLC diagnosis meets the trial's indication criteria and the prior treatments do not disqualify him. He has the required KRAS G12C mutation and his ECOG status is acceptable. Minor uncertainties exist regarding specific organ function lab results, but overall the profile indicates a high likelihood of eligibility.

---

### [NCT06562192](https://clinicaltrials.gov/study/NCT06562192)

**Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers**

- **Sponsor**: Novartis Pharmaceuticals
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65 years old
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- PD-L1: TPS 40%
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- No brain metastases
- Country: United States

**? Uncertainties:**
- Lesions showing 68Ga-NNS309 uptake

**Assessment:**
> The patient is diagnosed with Stage IV NSCLC, which directly matches the trial's inclusion criteria. They have received prior therapies, which is acceptable as per the trial's requirements for previously treated patients with actionable genomic alterations. However, confirmation on 68Ga-NNS309 uptake is needed.

---

### [NCT04956640](https://clinicaltrials.gov/study/NCT04956640)

**A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma) which matches the trial condition 'Non-Small-Cell Lung'.
- Patient has a confirmed KRAS G12C mutation.
- Patient has an ECOG status of 1 which is acceptable for the trial.
- Patient has no active brain metastases.
- Patient's organ function is adequate (creatinine 1.1, normal LFTs, ANC 3.2, platelets 245k).
- Patient is previously treated which aligns with the trial's allowance for such participants.

**Assessment:**
> The patient's cancer type and histology match the trial's indication for Non-Small-Cell Lung Cancer with KRAS G12C mutation. The patient has previously received systemic therapies, which aligns with the trial's inclusion criteria for previously treated patients. All other standard eligibility criteria are met.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of metastatic NSCLC (Stage IV).
- Patient has a documented KRAS G12C mutation.
- ECOG performance status is 1.
- Patient has no brain metastases.
- Patient has measurable disease (progressive disease noted).
- Patient's organ function parameters are within normal limits.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's indication for advanced solid tumors with KRAS p.G12C mutation. The patient has been treated previously, but the trial does not specify a requirement for treatment-naive patients, allowing for prior systemic treatments. All other eligibility criteria, including ECOG status and organ function, are met, supporting a high likelihood of eligibility.

---

### [NCT05985655](https://clinicaltrials.gov/study/NCT05985655)

**A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors**

- **Sponsor**: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- ECOG status: 1
- Cancer type: NSCLC
- No brain metastases
- Life expectancy > 3 months
- Prior therapies: carboplatin/pemetrexed and pembrolizumab (allows for progression to trial treatment)
- Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's conditions. The patient has a prior treatment history which aligns with the eligibility criteria for previously treated patients. The ECOG status, life expectancy, and absence of brain metastases further support eligibility.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is a target indication of the trial.
- Patient has KRAS G12C mutation, which is required for eligibility.
- Patient has ECOG status of 1, which is within the acceptable range.
- Patient has adequate organ function (creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k).
- Patient has received prior therapy and progressed, meeting the treatment line requirement.

**Assessment:**
> The patient's cancer type matches the trial's target indication, they meet the treatment line requirements, and have the necessary biomarker. Additionally, they meet all essential eligibility criteria.

---

### [NCT06975293](https://clinicaltrials.gov/study/NCT06975293)

**Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers**

- **Sponsor**: STORM Therapeutics LTD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- ECOG status 1
- Documented radiologic assessment of progression on prior therapy
- Metastatic Non-small Cell Lung Cancer (NSCLC)
- Prior anti-PD-1 therapy (pembrolizumab)
- No brain metastases

**? Uncertainties:**
- Requirement for measurable disease confirmation by the local site investigator/radiology must be verified

**Assessment:**
> The patient's cancer type of NSCLC aligns with the trialâ€™s target indications. The patient has received prior systemic treatment including an anti-PD-1 therapy and has documented disease progression, which aligns with the treatment line requirement. Thus, the patient likely meets eligibility criteria.

---

### [NCT07209111](https://clinicaltrials.gov/study/NCT07209111)

**A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a KRAS G12C mutation
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma) which is a solid tumor
- Patient is previously treated and fits within the trial's required therapy context

**Assessment:**
> The patient's cancer type is non-small cell lung cancer which aligns with the trial's focus on advanced solid tumors with KRAS G12C mutation. The patient has also received prior standard therapies and the trial seeks participants who have progressed on standard of care treatment. There are no conflicts noted against the eligibility criteria.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: NSCLC matches trial condition (Lung Non-Small Cell Carcinoma)
- ECOG status: 1 is acceptable
- Age: 65 is above 13 years old
- Biomarkers: KRAS G12C is not specifically mentioned as exclusion or inclusion, so acceptable
- PD-L1: TPS 40% is below the 50% threshold but not stated as an exclusion
- Country: United States is within jurisdictional limits for the trial

**âœ— Potential Conflicts:**
- Prior therapies: patient has received prior treatments (carboplatin/pemetrexed, pembrolizumab) but trial doesn't specify treatment line for further enrollment as this is a biobank study

**? Uncertainties:**
- Need to verify if archival tissue and current medical history align with collection requirements for biospecimen
- Confirmation required on the need for fresh tissue biospecimen at enrollment, which is not mentioned

**Assessment:**
> The patient's cancer type matches the trial's focus on NSCLC, and they fit within the required age and ECOG performance status. However, there are minor uncertainties concerning prior therapies and specific biospecimen collection requirements.

---

### [NCT05067283](https://clinicaltrials.gov/study/NCT05067283)

**A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is a condition studied in the trial.
- Patient has KRAS G12C mutation, which is required for trial participation.
- Patient is male and agrees to protocol-specified contraception.
- ECOG status is 1, which is acceptable for most trials.
- Patient has received at least 1 line of therapy for systemic disease.

**? Uncertainties:**
- None; all relevant information is provided.

**Assessment:**
> The patient's cancer type (NSCLC) aligns with the trial's focus on advanced solid tumors, and the patient has the necessary KRAS G12C mutation. He has already undergone prior treatment, fulfilling the trial's inclusion criteria for previously treated patients. No conflicts found, and the provided details confirm eligibility.

---

### [NCT06131840](https://clinicaltrials.gov/study/NCT06131840)

**An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors**

- **Sponsor**: Seagen, a wholly owned subsidiary of Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is included in the trial conditions
- Patient has received platinum-based therapy (carboplatin/pemetrexed)
- Patient has received PD-1/PD-L1 inhibitor (pembrolizumab)
- ECOG status is 1

**Assessment:**
> The patient's cancer type (NSCLC) matches the study's target indication. The patient's treatment history aligns with the eligibility criteria as they have received necessary prior therapies including platinum-based therapy and a PD-1/PD-L1 inhibitor. There are no conflicts or uncertainties regarding eligibility criteria.

---

### [NCT05799274](https://clinicaltrials.gov/study/NCT05799274)

**Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors**

- **Sponsor**: Radiopharm Theranostics, Ltd
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65 (â‰¥ 18 years)
- Sex: male
- Cancer type: NSCLC
- Biomarker: KRAS G12C
- ECOG status: 1
- PD-L1 TPS: 40%
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- Brain metastases: none
- Life expectancy judged by investigator â‰¥ 12 weeks
- Laboratory values: WBC 3.2, ANC 3.2 (â‰¥ 1000/Î¼L), Platelets 245k (â‰¥ 75,000/Î¼L), Creatinine 1.1 (â‰¤ 1.5 mg/dL)

**? Uncertainties:**
- SOC CT or MRI within 12 weeks prior to giving consent indicating new or residual disease
- Unremarkable ECG parameters (PR intervals and QTcF duration)
- Baseline pulse oximetry â‰¥ 95% on room air

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial focus and they meet the age and ECOG status requirements. While they are previously treated, the trial includes previously treated patients. They have the required biomarker KRAS G12C. Certain standard eligibility criteria, such as recent imaging and specific laboratory values, require further verification but do not exclude the patient at this stage.

---

### [NCT06150664](https://clinicaltrials.gov/study/NCT06150664)

**A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies**

- **Sponsor**: Compass Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced non-small cell lung cancer (NSCLC) which matches the trial's conditions studied.
- Patient has prior treatment with platinum-based chemotherapy (carboplatin/pemetrexed).
- Patient has received 2 doses of PD-1 therapy (pembrolizumab).
- ECOG status is 1, which is acceptable.
- Adequate renal function (creatinine 1.1 is normal), and normal liver function tests.
- No brain metastases.

**Assessment:**
> The patient's advanced NSCLC diagnosis matches the trial criteria, and he has received the required lines of therapy (prior treatments). There are no conflicting criteria, and all required information is confirmed.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is one of the conditions studied in the trial.
- Patient has received prior systemic therapy (carboplatin/pemetrexed + pembrolizumab) and has progressed, which meets the treatment line criteria for Arm #7 of the trial.
- Patient has KRAS G12C mutation, which aligns with the biomarker requirements for Arm #7 of the trial.
- ECOG status is 1, which is acceptable for participation.

**? Uncertainties:**
- Liver, renal function, and other lab values are normal based on typical thresholds but need explicit confirmation.
- No documented autoimmune or inflammatory disorders provided, but requires explicit verification as the trial has exclusions related to this.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's studied conditions, and they have prior systemic therapy, meeting the eligibility for a specific arm of the trial. The required biomarker (KRAS G12C mutation) is present, and ECOG status is acceptable. Minor uncertainties exist regarding liver and renal function confirmation.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histological diagnosis of Stage IV non-small cell lung cancer (adenocarcinoma)
- ECOG performance status of 1
- Confirmed KRAS G12C mutation

**Assessment:**
> The patient's cancer type matches the trial's focus on non-small cell lung cancer and has the required KRAS G12C mutation. The ECOG performance status meets trial criteria. There are no conflicting factors, and the patient has previously received systemic therapy, which aligns with the trial's inclusion criteria for treated patients.

---

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- PD-L1: TPS 40%
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- Brain metastases: none
- Creatinine: 1.1
- Turkey LFTs normal
- ANC: 3.2
- Platelets: 245k

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial focus. Treatment history indicates previous therapies, aligning with the trial's criteria for previously treated patients. All organ function criteria are met based on provided labs, supporting eligibility.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of NSCLC (adenocarcinoma) with KRAS G12C mutation
- Unresectable or metastatic disease (Stage IV with hepatic metastases)
- No available treatment with curative intent
- ECOG status of 1
- Adequate organ function evidenced by normal LFTs and creatinine 1.1
- No history of autoimmune disease
- No brain metastases

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's focus. The patient has previously received treatment but is not excluded as the trial has criteria for previously treated patients. There are no conflicts or uncertainties that impede eligibility.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (NSCLC) with KRAS G12C mutation
- ECOG status is 1, which is within the acceptable range
- Prior therapies include carboplatin/pemetrexed and pembrolizumab, qualifying as previously treated

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's indication. The patient is previously treated, which is acceptable for this trial. ECOG status is also within the acceptable limits.

---

### [NCT07090499](https://clinicaltrials.gov/study/NCT07090499)

**A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is aged 65, meeting the minimum age requirement of 18
- ECOG status is 1, which is eligible as per trial criteria
- Patient has advanced non-small cell lung cancer (NSCLC), which is included in the trial conditions
- Patient has measurable disease with hepatic metastases confirmed by imaging
- Patient has had up to 2 prior lines of systemic therapy, including carboplatin/pemetrexed and pembrolizumab, in the advanced setting

**Assessment:**
> The patient's cancer type (advanced NSCLC) matches the trial's indication, and the treatment history is appropriate for a previously treated population. All standard eligibility criteria are satisfied, leading to a high likelihood of eligibility.

---

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type matches: non-small cell lung cancer (NSCLC)
- Biomarker matches: KRAS G12C mutation present
- ECOG status of 1 is acceptable
- Has received prior standard therapy in the advanced setting (carboplatin/pemetrexed and pembrolizumab)

**? Uncertainties:**
- Adequate organ function not explicitly specified (e.g., liver function tests, blood counts)
- No details on recent blood transfusions or previous chemotherapy timing

**Assessment:**
> The patient's cancer type (NSCLC) and required KRAS mutation (G12C) match the trial criteria. The patient has received prior therapies qualifying for entry into the trial. No major exclusions are noted, but there are some uncertainties regarding organ function and recent treatment details.

---

### [NCT03551951](https://clinicaltrials.gov/study/NCT03551951)

**Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening**

- **Sponsor**: University of Missouri-Columbia
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient is 65 years old, which is above the minimum age of 18.
- Patient has a diagnosis of Non Small Cell Lung Cancer (NSCLC), which is a condition studied in this trial.
- Patient is capable of giving informed consent.
- Patient has no brain metastases.
- Patient has experienced prior systemic therapy, fitting potential inclusion as previously treated.

**âœ— Potential Conflicts:**
- Patient has received prior therapy (carboplatin/pemetrexed and pembrolizumab), yet the trial does not specify exclusion of previously treated patients.

**? Uncertainties:**
- The trial does not specify the treatment line requirement clearly (first-line vs. previously treated patients).
- Patient's LFTs and creatinine are within normal ranges, but specific eligibility criteria regarding these values are not confirmed.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's focus, and the patient meets the age and consent criteria. There is uncertainty about the specific treatment line requirements, but the trial does not explicitly exclude previously treated patients, allowing for a likelihood of eligibility.

---

## ðŸŸ¡ MEDIUM Likelihood (2 trials)

### [NCT05074810](https://clinicaltrials.gov/study/NCT05074810)

**A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Verastem, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has histologic evidence of NSCLC
- Patient has KRAS G12C mutation
- ECOG status is 1
- Patient has received appropriate treatment with prior systemic regimen
- No brain metastases

**? Uncertainties:**
- Organ function labs are not provided (e.g., liver, kidney) - considering laboratory values as uncertainties.

**Assessment:**
> The patient has Stage IV non-small cell lung cancer (NSCLC) with a confirmed KRAS G12C mutation, which matches the trial's indications. The patient has prior treatments and meets the ECOG status requirement. However, while they are likely eligible, the lack of specific organ function lab results adds some uncertainty to the evaluation.

---

### [NCT05501665](https://clinicaltrials.gov/study/NCT05501665)

**SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study**

- **Sponsor**: Vanderbilt-Ingram Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient is 65 years old, meeting age requirement (>= 18)
- ECOG status of 1 is acceptable.
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma) which matches the trial conditions studied.
- Currently asymptomatic with mild dyspnea on exertion.
- Available tumor material confirms KRAS G12C mutation.
- PD-L1 TPS of 40% meets the requirement for immunotherapy eligibility.

**âœ— Potential Conflicts:**
- Patient has received prior systemic therapies (carboplatin/pemetrexed and pembrolizumab) which may contradict criteria for treatment-naive patients, but the study details do not specifically exclude previously treated patients.

**? Uncertainties:**
- Organ function assessments (e.g., adequate organ function as determined by investigators) are not explicitly confirmed in the profile.

**Assessment:**
> The disease type is a match for the trial, and the patient's age and ECOG status satisfy the eligibility criteria. The uncertainties in organ function and previous treatment history create some ambiguity about overall eligibility.

---

## Excluded (64 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02143830](https://clinicaltrials.gov/study/NCT02143830) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04423029](https://clinicaltrials.gov/study/NCT04423029) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04929223](https://clinicaltrials.gov/study/NCT04929223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT04302025](https://clinicaltrials.gov/study/NCT04302025) | Genentech, Inc. | Patient's cancer is Stage IV NSCLC, while the trial includes only resectable early-stage NSCLC (IB-III). |
| [NCT04155034](https://clinicaltrials.gov/study/NCT04155034) | SWOG Cancer Research | Patient has non-small cell lung cancer (NSCLC), but the trial is only for small-cell lung cancer (SCLC). |
| [NCT04165070](https://clinicaltrials.gov/study/NCT04165070) | Merck Sharp & Dohme  | Patient has received prior systemic treatment (carboplatin/pemetrexed and pembrolizumab), while trial is for treatment-naive patients. |
| [NCT04613596](https://clinicaltrials.gov/study/NCT04613596) | Mirati Therapeutics  | Patient has prior systemic treatment (carboplatin/pemetrexed + pembrolizumab) which excludes eligibility for both Phase 2 and Phase 3 portions of the trial. |
| [NCT05789082](https://clinicaltrials.gov/study/NCT05789082) | Hoffmann-La Roche | Prior therapies: patient has had prior systemic treatment for advanced unresectable or metastatic NSCLC (carboplatin/pemetrexed + pembrolizumab) |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Amgen | Patient has prior therapy with carboplatin/pemetrexed and pembrolizumab, while the trial is for treatment-naive patients. |
| [NCT06246110](https://clinicaltrials.gov/study/NCT06246110) | Eikon Therapeutics | Patient has received prior systemic treatment for metastatic disease (carboplatin/pemetrexed, pembrolizumab) whereas the trial requires no prior systemic treatment for advanced/metastatic NSCLC. |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Merck Sharp & Dohme  | PD-L1 TPS is 40%, which is below the required threshold of â‰¥50% |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Daiichi Sankyo | Patient has prior systemic therapy for advanced disease (carboplatin/pemetrexed and pembrolizumab), while trial requires treatment-naive patients. |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | BioNTech SE | Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab), while the trial is looking for treatment-naive/first-line patients. |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Hoffmann-La Roche | Patient has prior systemic treatment for advanced NSCLC with pembrolizumab, which conflicts with the trial's requirement for no prior systemic treatment |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Mirati Therapeutics  | Patient has had prior systemic anti-cancer therapy (carboplatin/pemetrexed + pembrolizumab) whereas trial requires treatment-naive |
| [NCT07190248](https://clinicaltrials.gov/study/NCT07190248) | Merck Sharp & Dohme  | Patient has received prior systemic anticancer therapy for their advanced or metastatic NSCLC |
| [NCT07216404](https://clinicaltrials.gov/study/NCT07216404) | Alan Davis | Patient has previously treated NSCLC with systemic therapy (carboplatin/pemetrexed + pembrolizumab) but the trial does not specify if it accepts previously treated patients. |
| [NCT03260491](https://clinicaltrials.gov/study/NCT03260491) | Daiichi Sankyo | Trial requires documentation of EGFR activating mutations for Dose Escalation, patient has KRAS G12C mutation. |
| [NCT05430009](https://clinicaltrials.gov/study/NCT05430009) | VA Ann Arbor Healthc | Patient has no liver metastases, which is required for inclusion in the trial. |
| [NCT05866302](https://clinicaltrials.gov/study/NCT05866302) | University of Michig | Patient has NSCLC, while trial pertains to Chronic Lung Disease and Hematopoietic Cell Transplantation. No overlap between the cancer type and the trial conditions. |
| [NCT04665206](https://clinicaltrials.gov/study/NCT04665206) | Vivace Therapeutics, | Patient has prior systemic therapies (carboplatin/pemetrexed, pembrolizumab) but the trial requires treatment-naive patients. |
| [NCT05443126](https://clinicaltrials.gov/study/NCT05443126) | Ellipses Pharma | Patient has KRAS G12C mutation; trial requires RET-altered malignancies. |
| [NCT05786924](https://clinicaltrials.gov/study/NCT05786924) | Institut de Recherch | Patient has a KRAS G12C mutation, but trial is focusing on KRAS non-G12C mutations for Part 1A and Part 2A1. |
| ... | ... | *and 32 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| KRAS G12C lung adenocarcinoma | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
